Phoenix Bio

NEWS

NEWS

LATEST INFORMATION

July 19, 2018

Results from Studies using PXB-Mouse and PXB-cells being presented at ISSX 2018

June 29, 2018

Promotion of New President & CEO of PhoenixBio Co., Ltd. and PhoenixBio USA Corporation – Hiroshima, Japan, June 29th, 2018

Mr. Takashi Shimada has been promoted to President & CEO of PhoenixBio Co., Ltd. (Hiroshima, Japan) effective on June 28th, 2018. Mr. Kenji Kuramoto will continue as a Chairman of Board of Director of the company.

Mr. Yoshio Morikawa has been promoted to President & CEO of PhoenixBio USA Corporation (New York, NY, USA), a subsidiary of PhoenixBio Co., Ltd. effective on June 28th, 2018. Mr. Takashi Shimada will continue as a Chairman of Board of Director of the company.

May 15, 2018

Presentation & Booth Exhibition at ASGCT 2018

April 06, 2018

Results from Studies using PXB-Mouse and PXB-cells being presented at EASL 2018

March 02, 2018

Results from Studies using PXB-Mouse and PXB-cells being presented at Society of Toxicology 57th Annual Meeting and ToxExpo 2018

December 13, 2017

Result from Studies using PXB-Mouse and PXB-cells being presented at HepDART 2017

November 15, 2017

PhoenixBio Announces Strategic Acquisition of KMT Hepatech, Inc.

PhoenixBio Co., Ltd. today announced that it has entered into a definitive agreement to acquire KMT Hepatech, Inc., a privately held contract research organization focused on providing services with a chimeric mouse model. KMT will wholly become a part of the PhoenixBio group effective November 30th, 2017.

October 19, 2017

Result from Studies featuring PXB-mice & PXB-cells being presented at AASLD 2017